Charles Schwab’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$15.3M Buy
808,715
+1,466
+0.2% +$24.9K ﹤0.01% 1891
2025
Q4
$10.8M Buy
807,249
+173,547
+27% +$2.15M ﹤0.01% 2097
2025
Q3
$7.47M Buy
633,702
+35,490
+6% +$331K ﹤0.01% 2255
2025
Q2
$3.88M Buy
598,212
+34,908
+6% +$230K ﹤0.01% 2434
2025
Q1
$3.3M Sell
563,304
-30,052
-5% -$215K ﹤0.01% 2447
2024
Q4
$4.13M Sell
593,356
-9,188
-2% -$63.2K ﹤0.01% 2421
2024
Q3
$3.43M Buy
602,544
+46,187
+8% +$321K ﹤0.01% 2541
2024
Q2
$4.01M Buy
556,357
+359,143
+182% +$3.14M ﹤0.01% 2432
2024
Q1
$1.85M Buy
197,214
+5,340
+3% +$30.4K ﹤0.01% 2617
2023
Q4
$702K Buy
191,874
+3,338
+2% +$10.1K ﹤0.01% 2950
2023
Q3
$590K Buy
188,536
+8,727
+5% +$35.9K ﹤0.01% 2985
2023
Q2
$642K Buy
179,809
+859
+0.5% +$2.96K ﹤0.01% 2931
2023
Q1
$567K Sell
178,950
-2,517
-1% -$8.37K ﹤0.01% 2910
2022
Q4
$399K Buy
+181,467
New +$504K ﹤0.01% 3056
2022
Q2
Sell
-47,904
Closed -$798K 3607
2022
Q1
$798K Sell
47,904
-2,055
-4% -$35.7K ﹤0.01% 2941
2021
Q4
$1.03M Buy
49,959
+822
+2% +$26.2K ﹤0.01% 2900
2021
Q3
$1.72M Buy
49,137
+3,617
+8% +$156K ﹤0.01% 2734
2021
Q2
$2.36M Buy
+45,520
New +$2.39M ﹤0.01% 2660

Other funds holding DFTX

Charles Schwab's DFTX Position: Q1 2026 in Review

Charles Schwab increased its Definium Therapeutics (DFTX) stake by 0.18% in Q1 2026, buying an estimated $24.9K and bringing the position to 808,715 shares worth $15.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1891.

Charles Schwab first reported a position in DFTX in Q2 2021 and has held it in 18 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Charles Schwab held 808,715 shares of Definium Therapeutics worth $15.3M as of Q1 2026.
  • Charles Schwab bought 1,466 Definium Therapeutics shares in Q1 2026, an estimated $24.9K.
  • Definium Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q1 2026, its #1891 holding.
  • Charles Schwab first reported a position in Definium Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Charles Schwab's 13F filing for Q1 2026, filed 15 May 2026.